1 The study details 800 participants in the interim analysis (1,197 total enrolled) with biopsy-confirmed MASH and moderate to severe fibrosis (stage F2 or F3) Participants were randomly assigned to receive semaglutide 2.4 mg weekly or placebo Treatment lasted 72 weeks 2:1 randomisation (534 semaglutide, 266 placebo) Resolution of MASH (primary outcome) Fibrosis improvement (primary outcome) Combined outcomes About a third (32.7%) of participants taking semaglutide achieved both MASH resolution and fibrosis improvement, compared to 16.1% on placebo
Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques
GLP-1 Receptor Agonist Intolerance: When It May Be Time to Consider Endoscopic Sleeve Author By: Dr
Making it simple, stress-free, and easy for you to stay on top of your health, book your vitamin B12 injection now, or pop in to discuss.
Reddy's, a prominent Indian pharmaceutical company, has a long-standing focus on expanding its presence in crucial therapeutic areas, including diabetes management
Hard No